mTOR as a potential treatment target for epilepsy.
mTOR as a potential treatment target for epilepsy.
复制标题
DOI：
10.2217/fnl.12.45
复制
发表时间：
2012-09-01
期刊：
影响因子：
1.3
通讯作者：
Wong M
中科院分区：
文献类型：
--
作者：
Wong M
目前癫痫的治疗受到显著的限制，包括医学上的棘手性和缺乏疾病改善或抗癫痫作用。由于目前大多数癫痫药物调节离子通道和神经递质受体，更有效的治疗可能需要针对完全不同的作用机制。哺乳动物雷帕霉素靶蛋白（mTOR）通路是癫痫治疗的潜在新靶点。mTOR抑制剂可以在某些遗传性癫痫的动物模型中抑制癫痫发作并预防癫痫，例如结节性硬化症。mTOR抑制剂在某些与脑损伤相关的获得性癫痫模型中也可能有效，但这些作用更具可变性，并取决于许多因素。一些临床数据表明，mTOR抑制剂减少结节性硬化症患者的癫痫发作，但缺乏对照试验，也没有关于潜在抗癫痫作用的临床数据。未来的基础和临床研究将有助于确定mTOR抑制剂治疗癫痫的全部潜力。
Current treatments for epilepsy suffer from significant limitations, including medical intractability and lack of disease-modifying or anti-epileptogenic actions. As most current seizure medications modulate ion channels and neurotransmitter receptors, more effective therapies likely need to target completely different mechanisms of action. The mammalian target of rapamycin (mTOR) pathway represents a potential novel therapeutic target for epilepsy. mTOR inhibitors can suppress seizures and prevent epilepsy in animal models of certain genetic epilepsies, such as tuberous sclerosis complex. mTOR inhibitors may also be effective in some models of acquired epilepsy related to brain injury, but these effects are more variable and dependent on a number of factors. Some clinical data suggest that mTOR inhibitors decrease seizures in tuberous sclerosis complex patients, but controlled trials are lacking and no clinical data on potential anti-epileptogenic actions exist. Future basic and clinical research will help to determine the full potential of mTOR inhibitors for epilepsy.